A 6-Week, Multicenter, Masked, Randomized Trial (with a 20-Week Masked Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non Infectious Ocular Inflammation of the Anterior Segment in Patients with Anterior Uveitis To evaluate the safety and efficacy of the 700 µg DEX PS DDS Applicator System (700 µg dexamethasone) and 350 µg DEX PS DDS Applicator System (350 µg dexamethasone) compared with Sham DEX PS DDS Appli...

• Country None
• organs None
• Specialty None

A Double-Blind, Randomised, Cross-over, Safety and Efficacy Pilot Study Comparing Two Botulinum Toxin Type-A Products in the Treatment of Moderate to Severe Cervical Dystonia Primary Objective To compare the efficacy of intramuscular BOTOX® versus Xeomin® in the treatment of moderate to severe cervical dystonia.

• Country None
• organs None
• Specialty None

A study to compare a slow release formulation of bimatoprost with selective laser trabeculoplasty in patients with open-angle glaucoma or high pressure in the eye Un estudio para comparar una formulación de Bimatoprost de liberación prolongada con trabeculoplastia selectiva con láser en pacientes con glaucoma de ángulo abierto o hipertensión ocular To evaluate the IOP-lowering effect and safety of Bimatoprost SR compared with SLT in patients with OAG or OHT, who are not adequately managed with topical IOP-lowering medication for reasons other th...

• Country None
• organs None
• Specialty None

Treatment of Spasticity in the upper limb in children To evaluate the long-term safety of repeated doses of BOTOX for the treatment of pediatric upper limb spasticity.

• Country None
• organs None
• Specialty None

A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System To evaluate the biodegradation and related safety profile of the intravitreal Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS®) Implant

• Country None
• organs None
• Specialty None

Clinical Study of the safety and efficacy of Bimotoprost 0.03%/Timolol 0.5% Preservative-free Ophthalmic Solution compared with GANFORT®(Bimotoprost 0.03%/Timolol 0.5% Ophthalmic Solution) once daily for 12 weeks in Patients with Glaucoma or Ocular Hypertension To compare the efficacy and safety of bimatoprost 0.03%/ timolol 0.5% PF ophthalmic solution with GANFORT once-daily use for 12 weeks in patients with glaucoma or ocular hypertension (OHT). To show t...

• Country None
• organs None
• Specialty None

BOTOX® Treatment in Adult Patients with Upper Limb Spasticity To evaluate the safety and efficacy of BOTOX 300 U and 500 U in the treatment of spasticity involving the muscles of the elbow and shoulder of adult poststroke patients.

• Country None
• organs None
• Specialty None

A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Geographic Atrophy from Age-related Macular Degeneration To evaluate the safety of the Brimo PS DDS Applicator System (200 μg and 400 μg brimonidine tartrate) in patients with geographic atrophy (GA) from age-related macular degeneration (AMD) To evaluat...

• Country None
• organs None
• Specialty None

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Extension Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines) To evaluate the safety and efficacy of BOTOX compared to placebo in subjects with lateral canthal rhytides in the periorbital region (CFL).

• Country None
• organs None
• Specialty None

BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age To evaluate the safety and efficacy of BOTOX for the treatment of urinary incontinence due to OAB in patients 12 to 17 years of age who have not been adequately managed with anticholinergic therapy. T...

• Country None
• organs None
• Specialty None